Last updated: July 28, 2026
Bayer Intellectual Property GMBH v. Breckenridge Pharmaceutical Inc. (1:16-cv-00628): Litigation Summary, Claims, and Patent/Launch Risk
Bayer Intellectual Property GMBH brought patent infringement claims against Breckenridge Pharmaceutical Inc. in E.D. Texas under case number 1:16-cv-00628. The case centers on Bayer’s Orange Book–listed patent estate for a Bayer-branded product and Breckenridge’s proposed generic launch. The outcome affects (i) whether Breckenridge can launch “at risk” before expiry of the asserted patents and (ii) the strength of Bayer’s method-of-use and/or formulation patent coverage as typically litigated in E.D. Texas ANDA disputes.
What patents were asserted in Bayer Intellectual Property GMBH v. Breckenridge (1:16-cv-00628)?
Not provided in the available record. The case caption alone is insufficient to identify (a) the asserted patents, (b) the asserted claims, and (c) the Orange Book identifiers tied to the ANDA.
What products and Orange Book listings drove the dispute?
Not provided in the available record. Identification requires the FDA ANDA product name (NDA/ANDA reference listed drug), Orange Book publication, and the specific patents Bayer selected for infringement.
What infringement theories did Bayer plead (method-of-use, formulation, or device)?
Not provided in the available record. The litigation posture in ANDA cases can include multiple claim types, but the complaint and claim charts are needed to determine whether Bayer’s case leaned on:
- method-of-use claims (instructions for use)
- formulation claims (composition or polymorph)
- manufacturing-method claims
- patents tied to formulation changes or dosing regimens
What is the litigation timeline for 1:16-cv-00628 (filing, motions, Markman, and dispositive events)?
Not provided in the available record. A litigation timeline requires dates from the docket (complaint, answer, scheduling order, Markman, claim construction order, summary judgment, trial, and final judgment).
Key procedural milestones to extract from the docket
Not provided in the available record. These are the items typically used to compute litigation leverage and estimate generic entry timelines:
- service and answer dates
- Rule 12/53 motions practice
- Markman hearing and claim construction ruling date
- summary judgment dates on infringement and validity
- any stay events (common in E.D. Texas multiparty or related cases)
- final judgment and appellate notice dates
Did the court issue a Markman or summary judgment in Bayer v. Breckenridge (1:16-cv-00628)?
Not provided in the available record. Without the claim construction order and dispositive rulings, the analysis cannot determine:
- whether Bayer’s claim scope survived construction
- whether Breckenridge won on non-infringement or invalidity
- whether the asserted claims were narrowed or invalidated
How did claim construction affect infringement strength?
Not provided in the available record. Claim construction results are the main driver of whether a generic product avoids infringement through design-arounds or claim-limitations.
What did Breckenridge argue in its defenses (non-infringement, invalidity, unenforceability, or design-around)?
Not provided in the available record. ANDA defendants typically pursue combinations of:
- § 112 indefiniteness or written description issues
- obviousness/anticipation under § 102/103
- lack of enablement under § 112
- prosecution history estoppel
- inequitable conduct or enforceability defenses (less common unless specifically pleaded)
What grounds were used for invalidity challenges?
Not provided in the available record. A valid analysis requires the prior art set, anticipation/obviousness theories, and the court’s rulings.
How did patent expiration and exclusivity timelines factor into the case outcome?
Not provided in the available record. A litigation outcome in ANDA cases is often interpreted relative to:
- earliest patent expiration among asserted patents
- pediatric exclusivity extensions
- Hatch-Waxman 30-month stay timing (tied to ANDA submission and patent listing)
- any Roche/Boehringer-type regulatory exclusivity (if applicable)
What was the Orange Book status of Bayer’s patents at the time of filing?
Not provided in the available record. Orange Book analysis requires:
- the RLD name
- publication numbers
- listed patents and their expiration dates
- whether patents are “drug substance,” “drug product,” “method of use,” or “exclusivity” codes
What Paragraph IV or non-infringement challenges did Breckenridge pursue?
Not provided in the available record. A full Hatch-Waxman posture requires the specific certification paragraph (IV, I, II, III), filing date, and whether FDA approved a tentative approval subject to litigation outcomes.
What settlement or consent judgment resolved Bayer v. Breckenridge (1:16-cv-00628)?
Not provided in the available record. Settlement analysis needs:
- whether a covenant-not-to-sue or dismissal with prejudice occurred
- any stipulated effective date for launch
- any “carve-out” for certain strengths, dosages, or labeling
- whether a payment for delay occurred (often discussed in antitrust litigation, but that would require separate dockets)
How strong was Bayer’s patent estate in this litigation?
Not provided in the available record. Without:
- asserted patent numbers
- court rulings on validity/infringement
- survival of claims after Markman
any estimate of “strength” would be speculative.
Was the estate primarily method-of-use, formulation, or manufacturing?
Not provided in the available record.
What was the geographic scope effect (U.S. only, nationwide injunction vs. local practice)?
Not provided in the available record. Injunction scope depends on judgment type and any stays pending appeal.
What generic entry risks existed for Breckenridge if it lost (or won) this case?
Not provided in the available record. Risk depends on:
- whether the court enjoined infringement (and for which patents/claims)
- whether non-infringement verdict permitted immediate launch
- whether any appeal stayed enforcement
Launch timing scenarios analysts model in ANDA disputes
Not provided in the available record. In this case, modeling would require:
- which patents were finally adjudicated
- expiration dates for the specific asserted patents
- the presence of any injunction or stipulated launch calendar
How does this case compare with other Bayer v. Breckenridge patent disputes?
Not provided in the available record. Comparison requires either related case numbers or a list of parallel litigations involving the same product, same defendant, or related patents.
Key Takeaways
- Case identified: Bayer Intellectual Property GMBH v. Breckenridge Pharmaceutical Inc., E.D. Texas, 1:16-cv-00628.
- Litigation issue type: Hatch-Waxman style patent infringement dispute tied to an ANDA and Bayer’s Orange Book–listed patent estate.
- Court and patent specifics absent: The record provided does not include asserted patent numbers, claim counts, docket timeline, rulings, or settlement terms, so the analysis cannot map legal leverage to specific patent claims or quantify generic launch exposure.
FAQs
- What product (RLD/ANDA) was the subject of 1:16-cv-00628?
- Which specific Bayer patents were asserted in the complaint and which claims were targeted?
- Did the court construe the disputed claims, and what limitations did it adopt?
- Was there an injunction, dismissal, or settlement that defined the generic launch date?
- How did the case affect Breckenridge’s ability to market the generic in specific strengths or dosage forms?
References
- U.S. District Court, Eastern District of Texas. Bayer Intellectual Property GMBH v. Breckenridge Pharmaceutical Inc., No. 1:16-cv-00628. (Docket and filings not included in the provided record.)
